The upcoming EU Biotech Act may be more prominently focused on health. But it will also significantly impact food and food ...

Burcon NutraScience (TSX: BU), a global technology leader in plant-based protein innovation, announced that a study conducted ...

Concerto Biosciences®, a clinical-stage biotech company developing microbial products for therapeutics and consumer markets, today announced positive topline results from its first-in-human Phase 1b ...

Australia's first genetically modified banana has been tweaked to protect it from a disease that's on the verge of wiping out ...

Iowa State University researchers have unlocked new secrets within the bacteria responsible for the creation of thousands of fruits and vegetables as we know them today, with the goal of seeing how ...

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them. The big banks have started off the new earnings-reporting ...

Recursion Pharmaceuticals developed a promising artificial intelligence (AI) platform for drug discovery and development. The company's clinical-stage pipeline is just the tip of the iceberg of its ...

LONDON, Oct 15 (Reuters) - German biotech firm Tubulis said on Wednesday it had raised 308 million euros ($358 million) in its biggest financing round to date, contributing to a total of 495 million ...

Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. LONDON — The German biotech Tubulis, which is designing a series of ...

Re “Harvard Finds Skipping Class Part of Culture” (front page, Oct. 8): If Harvard wants students to attend class, there’s a simple solution: Make in-person attendance mandatory, and don’t allow any ...

A rebound in global biotech deals is set to accelerate as big pharmaceutical companies seek new sources of revenue, according to the International Biotechnology Trust Plc. The pace of dealmaking has ...